TBG Diagnostics Limited, Medigen Corp. and National Taiwan University Hospital Enter Exclusive Licensing Agreement for the Development and Distribution of Patented Product for Evaluation of Adverse Reaction in Antithyroid Drug
March 12, 2017 at 07:19 pm EDT
The Board of TBG Diagnostics Limited announced that in association with Medigen Corp. it has entered into an Exclusive Licensing Agreement with the National Taiwan University Hospital (NTUH) for development and distribution of a patented product that is designed to evaluate adverse reactions to antithyroid drugs. With the signing of the Agreement, the TBG Medigen partnership will obtain the worldwide exclusive right to develop and distribute an invitro diagnostic (IVD) product that can identify and prevent patients suffering Grave's Disease (GD) from developing further life-threatening agranulocytosis after taking Thionamide drugs. In order to prevent Thionamide induced agranulocytosis (TiA) in GD patients, Professor Chang, Tien-Chun of NTUH, Associate Professor Chen, Pei-Lung of Graduate Institute of Medical Genomics and Proteomics at National Taiwan University and his team at the NTUH were able to identify, publish two Human Leukocyte Antigen (HLA) alleles and obtain patents that are able to predict increased risk of TiA. The signing of this exclusive licensing agreement will allow TBG to develop HLA IVD products or services that can identify individuals who are at risk for TiA.